4D Molecular Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
FDMT$12.48+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Comprehensive Loss
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Net loss | $(140,109) | $(160,868) |
| Other comprehensive loss: | ||
| Net unrealized gain on marketable securities | 498 | 213 |
| Total comprehensive loss | $(139,611) | $(160,655) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.